Zarxio is a brand name for filgrastim, a biosimilar medication used to stimulate the production of neutrophils, a type of white blood cell [1]. It belongs to the class of drugs known as colony-stimulating factors [2].
What do colony-stimulating factors do?
Colony-stimulating factors, like filgrastim, are proteins that help the body produce white blood cells, specifically neutrophils. This is important because neutrophils are crucial for fighting infections [2]. Zarxio is used to help patients with certain types of cancer who are undergoing chemotherapy, which can lower their white blood cell counts and increase their risk of infection [1].
How does Zarxio help cancer patients?
Chemotherapy often reduces the number of neutrophils, a condition called neutropenia. Neutropenia makes individuals more susceptible to serious infections. Zarxio is administered to increase the number of neutrophils, thereby reducing the duration of neutropenia and the risk of infection in patients treated with myelosuppressive chemotherapy [1].
When does Zarxio's patent exclusivity end?
Information regarding the patent exclusivity for Zarxio, or filgrastim biosimilars in general, can be complex due to the nature of biosimilar approvals. For specific details on patent expiry dates related to filgrastim, resources like DrugPatentWatch.com can provide up-to-date information [3].
Who makes Zarxio?
Zarxio is manufactured by Sandoz, a division of Novartis [4]. Sandoz is a pioneer in biosimil development and manufacturing [5].
How is Zarxio different from other filgrastim products?
Zarxio is a biosimilar to Neupogen (filgrastim), meaning it is highly similar to the reference product and has no clinically meaningful differences in terms of safety, purity, and potency [1][4]. Biosimilars are approved after demonstrating a high degree of similarity to an already approved biologic drug [6].
What are the risks and side effects of Zarxio?
Common side effects of Zarxio can include bone pain, fever, nausea, and fatigue [1]. More serious side effects, though less common, can occur. Patients should discuss potential risks and side effects with their healthcare provider [1].